“The probability of a near-term equity raise depends on how the share price responds to FDA approval in CD and to the 2Q23 financial results.”
Speaking of probabilities, one of the reasons I invested in RVNC was the notion they would be eventually bought out at a market capitalization of $4-5 Billion after the FDA granted approval for the medical treatment of CD and a pathway to profitability.
Do you (and others here) still believe this is viable opportunity for the company to be purchased outright? TIA
News 
Market Data 
Discover 
AI
